Perspectives of arterial hypertension control improvement by rational diuretic therapy: Russian research and clinical program ARGUS-2 results
Abstract
Aim. As a part of ARGUS-2 program, to demonstrate the reserves for arterial hypertension (AH) control improvement, by rational monotherapy or combined therapy with diuretics in patients with uncontrolled AH in anamnesis: individuals with isolated systolic AH (ISAH), diabetes mellitus (DM), chronic nephropathy (CN), and metabolic syndrome (MS).
Material and methods. This open, non-comparative study, without washout period, included 1438 patients (mean age 57,3±10,7 years, blood pressure, BP 158,8±14,2/93,4±10,0 mm Hg), not achieving target BP levels (<140/<90 mm Hg or <130/<80 mm Hg for DM or CN), and receiving non-diuretic therapy. Slow-release indapamide (Arifon® retard), in the dose of 1,5 mg, was administered once per day. Follow-up period lasted for 3 months. To achieve target BP levels, the physician could modify antihypertensive treatment regimen.
Results. In total, 1399 patients (97,3%) completed the study. Arifon® retard was administered as monotherapy in 13,7% of the participants; as an alternative to previous ineffective monotherapy – in 6,8%; in addition to inadequately effective monotherapy – in 31,9%; and in addition to inadequately effective non-diuretic therapy – in 47,6%. Three months later, target BP level rate was 84,5%, mean BP level reduced to 131,8±9,7/80,5±6,9 mm Hg. Target BP was achieved in 91,9% (n=477) of ISAH patients, in 74,8% (n=214) of DM participants, in 75,6% (n=82) of CN individuals, and in 85,1% (n=745) of MS patients.
Conclusion. The study results confirmed the importance of low-dose thiazide diuretic therapy, as a part of combined treatment, in achieving target BP levels among patients with high or very high cardiovascular risk.
About the Authors
Zh. D. Kobalava
Российский университет дружбы народов, Москва
Russian Federation
Russian Federation
Yu. V. Kotovskaya
Российский университет дружбы народов, Москва
Russian Federation
Russian Federation
S. V. Villevalde
Russian University of People’s Friendship, Moscow
Russian Federation
Russian Federation
References
1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension 2003; 42: 1206-52.
2. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-92.
3. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
4. Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (второй пересмотр). Приложение Кардиваск тер профил 2004; 20 с.
5. Кобалава Ж.Д., Склизкова Л.А., Котовская Ю.В. и др. Представления об артериальной гипертонии у пожилых и реальная клиническая практика в России (результаты I этапа российской научно-практической программы АРГУС). Кардиология 2001;11: 51-7.
6. Кобалава Ж.Д., Котовская Ю.В., Старостина Е.Г. и др. от имени исследователей АРГУС-2. Проблемы взаимодействия «врач-пациент» и контроль артериальной гипертонии в России. Основные результаты Российской научно-практической программы АРГУС-2. Кардиология 2007; 3: в печати.
7. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289: 2534-44.
8. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hipertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blockers diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
9. Moser M. Diuretics should continue to be one of the preferred initial therapies in the management of hypertension. The argument for. J Clin Hypertens 2005; 7: 111-6.
10. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410-9.
11. Kostis JB, Wilson AC, Fredenberger RS, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005; 95: 29-35.
12. Ong KL, Cheung BMY, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49: 69-75.
13. Шальнова С.А., Деев А.Д., Вихирева О.В. и др. Распространенность артериальной гипертонии в России. Информированность, лечение, контроль. Профил забол укреп здор 2001; 2: 3-7.
14. Шальнова С.А., Деев А.Д., Оганов Р.Г. Факторы, влияющие на смертность от сердечно-сосудистых заболеваний в российской популяции. Кардиоваск тер профил 2005; 1:4-9.
15. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
16. National Kidney Foundation Guideline. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002; 39: S1-246.
17. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865-72.
18. Lloyd-Jones DM, Evans JC, Larson MG, et al. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 2000; 36: 594-9.
19. Кобалава Ж.Д., Котовская Ю.В., Верещагина Г.Н. и др. Эффективность и переносимость индапамида ретард при лечении артериальной гипертонии у больных пожилого возраста (результаты многоцентрового открытого несравнительного исследования в рамках Российской научно-практической программы АРГУС). Кардиология 2002; 7: 63-8.
20. Мычка В.Б., Чазова И.Е. от имени исследователей. Российская доказательная медицина – программа МИНОТАВР: преимущества ретардной офрмы индапамида при лечении метаболического синдрома. Cons Med 2006; 8(5): 17-21.
21. Akram J. Antihypertensive efficacy of indapamide sr in hypertensive patients uncontrolled with a background therapy: the NATIVE study. J Hypertens 2006; 24(Suppl. 4): S93.
Review
For citations:
Kobalava Zh.D., Kotovskaya Yu.V., Villevalde S.V. Perspectives of arterial hypertension control improvement by rational diuretic therapy: Russian research and clinical program ARGUS-2 results. Cardiovascular Therapy and Prevention. 2007;6(3):61-67. (In Russ.)
Views:
510
Email this article 
